咨询与建议

看过本文的还看了

相关文献

该作者的其他文献

文献详情 >Base Excision Repair Inhibitio... 收藏

Base Excision Repair Inhibition by Methoxyamine Impairs Growth and Sensitizes Osteosarcoma Cells to Conventional Treatments

Base Excision Repair Inhibition by Methoxyamine Impairs Growth and Sensitizes Osteosarcoma Cells to Conventional Treatments

作     者:Ana Paula Montaldi Julia Alejandra Pezuk Elza Tiemi Sakamoto-Hojo Luiz Gonzaga Tone María Sol Brassesco 

作者机构:Department of Biology Faculty of Philosophy Sciences and Letters at Ribeirao Preto University of Sao Paulo Sao Paulo Brazil Department of Genetics Faculty of Medicine of Ribeirao Preto University of Sao Paulo Sao Paulo Brazil Department of Pediatrics Faculty of Medicine of Ribeirao Preto University of Sao Paulo Sao Paulo Brazil 

出 版 物:《Journal of Cancer Therapy》 (癌症治疗(英文))

年 卷 期:2014年第5卷第4期

页      面:307-314页

学科分类:1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主  题:Osteosarcoma Methoxyamine BER Cell Lines 

摘      要:The outcome of patients with osteosarcoma has not significantly improved in the last three decades. Therefore, there is still a need for the development of more effective therapeutic strategies. Methoxyamine (MX) is a base excision repair (BER) inhibitor that has shown anticancer potential by sensitizing a variety of tumor cells to ionizing radiation and chemotherapeutic drugs. In the present study, the in vitro antiproliferative effects of MX were evaluated in two osteosarcoma cell lines, HOS and MG-63. Evaluation of the influence on radiosensitivity and drug interactions in simultaneous treatments with methotrexate, doxorubicin, and cisplatin was also performed. Exposure to MX significantly decreased cell proliferation and mediated a substantial increase of apoptosis. Moreover, our results showed that MX synergized with ionizing radiation in both cell lines while potentiated the antitumor effects of cisplatin and methotrexate. Altogether, the results presented herein demonstrate the feasibility of inhibiting the BER pathway, which may in future be a promising strategy for overcoming intrinsic tumor resistance and to improve the outcome of patients with osteosarcoma.

读者评论 与其他读者分享你的观点

用户名:未登录
我的评分